- SNS-314
-
- $3100.00
-
2026-04-20
- CAS:1057249-41-8
- Purity:
- Supply Ability: 10g
|
| | N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea Basic information |
| Product Name: | N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea | | Synonyms: | N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea;1-(3-chlorophenyl)-3-(4-(2-(thieno[3,2-d]pyriMidin-4-ylaMino)ethyl)thiazol-2-yl)urea;SNS314;SNS 314;CS-901;Urea, N-(3-chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]-;1-(3-chlorophenyl)-3-(5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-2-yl)urea;SNS-314 free base;SNS-314 | | CAS: | 1057249-41-8 | | MF: | C18H15ClN6OS2 | | MW: | 430.94 | | EINECS: | | | Product Categories: | api | | Mol File: | 1057249-41-8.mol | ![N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea Structure](CAS2/GIF/1057249-41-8.gif) |
| | N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea Chemical Properties |
| density | 1.588 | | storage temp. | Store at -20°C | | solubility | DMSO: 100 mg/mL (232.06 mM);Ethanol: Insoluble | | pka | 6.12±0.70(Predicted) | | Water Solubility | Water: Insoluble | | InChI | InChI=1S/C18H15ClN6OS2/c19-11-2-1-3-12(8-11)24-17(26)25-18-21-9-13(28-18)4-6-20-16-15-14(5-7-27-15)22-10-23-16/h1-3,5,7-10H,4,6H2,(H,20,22,23)(H2,21,24,25,26) | | InChIKey | FAYAUAZLLLJJGH-UHFFFAOYSA-N | | SMILES | N(C1=CC=CC(Cl)=C1)C(NC1=NC=C(CCNC2N=CN=C3C=CSC3=2)S1)=O |
| | N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea Usage And Synthesis |
| Uses | SNS-314 is used in the synthesis of AuroraA kinase inhibitors used in cancer treatment. | | Definition | ChEBI: 1-(3-chlorophenyl)-3-[5-[2-(4-thieno[3,2-d]pyrimidinylamino)ethyl]-2-thiazolyl]urea is a member of ureas. | | in vivo | In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 leads to dose-dependent inhibition of histone H3 phosphorylation for at least 10 h. SNS-314 shows significant tumor growth inhibition in a dose dependent manner under a variety of dosing schedules including weekly, bi-weekly, and 5 days on/9 days off[2]. | | IC 50 | Aurora A: 9 nM (IC50); Aurora B: 31 nM (IC50); Aurora C: 6 nM (IC50) |
| | N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea Preparation Products And Raw materials |
|